You are here

Canagliflozin + metformin demonstrated superior reductions in systolic blood pressure (BP) vs sitagliptin 100 mg + metformin at 52 weeks1

Secondary Endpoint: Adjusted Mean Change in Systolic BP From Baseline at 52 Weeks (mm Hg)


Reductions in systolic blood pressure: canagliflozin 100 mg plus metformin and canagliflozin 300 mg plus metformin vs sitagliptin 100 mg plus metformin Reductions in systolic blood pressure: canagliflozin 100 mg plus metformin and canagliflozin 300 mg plus metformin vs sitagliptin 100 mg plus metformin
  • Canagliflozin 100 mg difference from sitagliptin: –2.9 mm Hg (95% CI: –4.5, –1.3; P <0.001)
  • Canagliflozin 300 mg difference from sitagliptin: –4.0 mm Hg (95% CI: –5.6, –2.4; P <0.001)

Canagliflozin is not indicated as an antihypertensive treatment.

SELECT IMPORTANT SAFETY INFORMATION FROM PRESCRIBING INFORMATION

  • Canagliflozin results in an osmotic diuresis, which may lead to reductions in intravascular volume. In clinical studies, the incidence of volume depletion–related adverse reactions was 2.3% and 3.4% with canagliflozin 100 mg and 300 mg, respectively, vs 1.5% in comparator groups. The risk of these adverse events was increased in patients with impaired renal function (eGFR 30 to <60 mL/min/1.73 m2), elderly patients, and patients on loop diuretics2 

Study Design

A double-blind, placebo- and active-controlled study of 1284 patients who were inadequately controlled on metformin alone. Study consisted of a 2-week, single-blind, placebo run-in period, a 26-week, placebo- and active-controlled treatment period (period 1) followed by a 26-week, active-controlled treatment period (period 2). Patients were randomized to the addition of canagliflozin 100 mg, canagliflozin 300 mg, sitagliptin 100 mg, or placebo. The primary endpoint was the change in A1C from baseline through week 26; change in A1C from baseline through week 52 was a prespecified secondary endpoint.1

Learn about SAFETY

See the results of INVOKANA® AS MONOTHERAPY, VS JANUVIA®, VS GLIMEPIRIDE, in PATIENTS WITH RENAL IMPAIRMENT, and in OLDER PATIENTS.

References: 1.  Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582-2592. Supplemental tables available at: http://link.springer.com/article/10.1007%2Fs00125-013-3039-1. Accessed September 1, 2016. 2.  INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.